ストックスクリーナーアプリを入手
3.58
9.78%
-0.388
前日終値:
$3.968
開ける：
$3.92
24時間の取引高:
263.34K
Relative Volume:
1.24
時価総額：
$8.82M
収益：
$895.50K
当期純損益:
$-26.30M
株価収益率:
-2.1829
EPS:
-1.64
ネットキャッシュフロー:
$-23.84M
1週間 パフォーマンス:
-21.83%
1か月 パフォーマンス:
-40.73%
6か月 パフォーマンス:
-63.77%
1年 パフォーマンス:
-91.31%
1日の値動き範囲:
$3.29
$3.9873
1週間の範囲:
$3.29
$4.797
52週間の値動き範囲:
$3.29
$45.20
Mainz Biomed N V Stock (MYNZ) Company Profile
MYNZ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MYNZ
Mainz Biomed N V
|
3.58 | 8.82M | 895.50K | -26.30M | -23.84M | -1.64 |
|
TMO
Thermo Fisher Scientific Inc
|
500.16 | 196.14B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
205.85 | 150.17B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
415.87 | 34.36B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
116.69 | 33.28B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
177.39 | 31.62B | 15.41B | 1.37B | 2.11B | 7.50 |
Mainz Biomed N V Stock (MYNZ) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-14 | 開始されました | Maxim Group | Buy |
| 2024-11-25 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-21 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-21 | 開始されました | H.C. Wainwright | Buy |
Mainz Biomed N V (MYNZ) 最新ニュース
Mainz Biomed Enrolls First Patient In EAArly DETECT 2 Study To Advance Colorectal Cancer Test - Nasdaq
Mainz Biomed begins pivotal colorectal cancer test study - Investing.com
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - GlobeNewswire
Revolutionary AI-Powered Cancer Test: Mainz Biomed Begins Major Clinical Trial - StockTitan
(MYNZ) Proactive Strategies - Stock Traders Daily
Mainz Biomed secures license for pancreatic cancer test By Investing.com - Investing.com Australia
Mainz Biomed Licenses MRNA Biomarkers For Non-Invasive Pancreatic Cancer Screening Test - Nasdaq
Mainz Biomed, Liquid Biosciences Partner on Blood-Based Test for Pancreatic Cancer - Marketscreener.com
Mainz Biomed’s Breakthrough in Pancreatic Cancer Detection - TipRanks
Mainz Biomed secures license for pancreatic cancer test - Investing.com India
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer - The Manila Times
Mainz Biomed Signs Exclusive Licensing Agreement with Liquid Biosciences for Novel mRNA Biomarkers in Pancreatic Cancer Detection - Nasdaq
Mainz Biomed and Liquid Biosciences Make Groundbreaking - GlobeNewswire
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood ... - The Bakersfield Californian
Revolutionary mRNA Blood Test Detects Pancreatic Cancer with Near-Perfect Accuracy - StockTitan
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention - GlobeNewswire
Can Mainz Biomed's 82% Detection Rate Technology Revolutionize Colorectal Cancer Prevention? - StockTitan
(MYNZ) Trading Advice - Stock Traders Daily
Mainz Biomed Expands into Switzerland with labor team w - GlobeNewswire
Mainz Biomed Partners with labor team w ag to Launch ColoAlert® Colorectal Cancer Screening Test in Switzerland - Nasdaq
First DNA-Based Cancer Test Enters Swiss Market: Can Mainz Biomed Transform Screening? - StockTitan
Mainz Biomed (NASDAQ:MYNZ) Coverage Initiated at Maxim Group - Defense World
Maxim Group Initiates Coverage of Mainz Biomed N.V. (MYNZ) with Buy Recommendation - Nasdaq
This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
How To Trade (MYNZ) - Stock Traders Daily
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced - GlobeNewswire
Mainz Biomed Collaborates with GANZIMMUN Diagnostics to Launch Enhanced ColoAlert Colorectal Cancer Screening Test in Germany - Nasdaq
Mainz Biomed's Revolutionary DNA Tech Powers New German Cancer ScreeningWhat Sets It Apart - StockTitan
A stock that deserves closer examination: Mainz Biomed N.V (MYNZ) - US Post News
The Future of Mainz Biomed N.V: Analyzing MYNZ - The InvestChronicle
Mainz Biomed regains Nasdaq compliance with equity rule By Investing.com - Investing.com Canada
Mainz Biomed regains Nasdaq compliance with equity rule - MSN
Mainz Biomed Regains Nasdaq Listing Compliance - TipRanks
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements - GlobeNewswire
Mainz Biomed Achieves Full Nasdaq Compliance, Secures Market Position - StockTitan
Mainz Biomed Regains Compliance With Nasdaq Listing Rules - Nasdaq
Mainz Biomed (MYNZ) Stock Price, News & Analysis - MarketBeat
Mainz Biomed (NASDAQ:MYNZ) Shares Down 3.7% – What’s Next? - Defense World
Mainz Biomed Initiates U.S. Clinical Study to Evaluate - GlobeNewswire
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on - The Bakersfield Californian
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Marketscreener.com
Mainz Biomed Moves Forward With Pivotal CRC Study After Feasibility Trial - Nasdaq
Mainz Biomed B.V. Addresses Nasdaq Listing Compliance Issue - TipRanks
Mainz Biomed (NASDAQ:MYNZ) Stock Price Down 5.3% – Here’s Why - Defense World
MYNZMainz Biomed N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Mainz Biomed N.V. Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test - Marketscreener.com
Mainz Biomed Partners with Quest Diagnostics to Advance Colorectal Cancer Screening in the U.S. - Citybuzz
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. - Nasdaq
Mainz Biomed (MYNZ) Stock Soars In Pre-Hour Session On A New Partnership - Stocks Telegraph
Mainz Biomed stock higher on Quest deal (MYNZ:NASDAQ) - Seeking Alpha
Mainz Biomed partners with Quest for colorectal cancer test - Investing.com
Mainz Biomed N V (MYNZ) 財務データ
収益
当期純利益
現金流量
EPS
0.80%
0.71%
大文字化:
|
ボリューム (24 時間):